Five things for pharma marketers to know: Tuesday, May 16, 2017
A New York county sues drugmakers over opioid marketing; AstraZeneca files suit against GSK exec; Thermo Fisher acquires biologics firms
A New York county sues drugmakers over opioid marketing; AstraZeneca files suit against GSK exec; Thermo Fisher acquires biologics firms
Josephine Martin was previously EVP of public affairs at PhRMA.
Tesaro discloses price for new drug that differs from FDA-approved dosage; uniQure discontinues Glybera; O’Reilly leaves Fox
Pacira also recently announced a partnership with Johnson & Johnson to co-promote its pain injection for certain surgeries.
Novartis CAR-T drug receives priority review; addiction center’s ad compares addiction to cancer; Arizona passes off-label law
The committee is seeking information about the companies’ sales and marketing strategies.
PBMs’ use of “clawbacks” prompt lawsuits; Merck’s experimental antiviral drug prevents infection; EMA recommends Novartis’ lung-cancer combo drug
Sanofi to sell five OTC drugs to Ipsen; Teva reports 33% revenue growth in Q4; Regeneron issued subpoena about support of nonprofits
Illumina and IBM enter DNA sequencing partnership; J&J to outline price increases in new report; Egalet’s opioid Arymo ER gets FDA approval
Drugmakers promote new type of opioid with unproven results; Heritage execs charged for price-fixing generics; Pershing sells more Valeant shares